Significant Improvement in Survival After Allogeneic Hematopoietic Cell Transplantation During a Period of Significantly Increased Use, Older Recipient Age, and Use of Unrelated Donors
Authors:
- Theresa HahnTHTheresa Hahn
- Philip L. McCarthyPMPhilip L. McCarthy
- Anna HassebroekAHAnna Hassebroek
- Christopher BredesonCBChristopher Bredeson
- James L. GajewskiJGJames L. Gajewski
- Gregory A. HaleGHGregory A. Hale
- Luis M. IsolaLILuis M. Isola
- Hillard M. LazarusHLHillard M. Lazarus
- Stephanie J. LeeSLStephanie J. Lee
- Charles F. LeMaistreCLCharles F. LeMaistre
- Fausto LoberizaFLFausto Loberiza
- Richard T. MaziarzRMRichard T. Maziarz
- 1 July 2013
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (19) , 2437-2449
Abstract
Purpose: Over the past four decades, allogeneic hematopoietic cell transplantation (alloHCT) has evolved as a curative modality for patients with hematologic diseases. This study describes changes in use, technique, and survival in a population-based cohort. Patients and Methods: The study included 38,060 patients with hematologic malignancies or disorders who underwent first alloHCT in a US or Canadian center from 1994 to 2005 and were reported to the Center for International Blood and Marrow Transplant Research. Results: AlloHCT as treatment for acute lymphoblastic (ALL) and myeloid leukemias (AML), myelodysplastic syndrome (MDS), and Hodgkin and non-Hodgkin lymphomas increased by 45%, from 2,520 to 3,668 patients annually. From 1994 to 2005, use of both peripheral (7% to 63%) and cord blood increased (2% to 10%), whereas use of marrow decreased (90% to 27%). Despite a median age increase from 33 to 40 years and 165% increase in unrelated donors for alloHCT, overall survival (OS) at day 100 significantly improved for patients with AML in first complete remission after myeloablative sibling alloHCT (85% to 94%; P < .001) and unrelated alloHCT (63% to 86%; P < .001); 1-year OS improved among those undergoing unrelated alloHCT (48% to 63%; P = .003) but not among those undergoing sibling alloHCT. Similar results were seen for ALL and MDS. Day-100 OS after cord blood alloHCT improved significantly from 60% to 78% (P < .001) for AML, ALL, MDS, and chronic myeloid leukemia. Use of reduced-intensity regimens increased, yielding OS rates similar to those of myeloablative regimens. Conclusion: Survival for those undergoing alloHCT has significantly improved over time. However, new approaches are needed to further improve 1-year OS.Keywords
This publication has 14 references indexed in Scilit:
- Improved Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Recent Years. A Single-Center StudyTransplantation and Cellular Therapy, 2011
- Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313Blood, 2009
- Advances in the Selection of HLA-Compatible Donors: Refinements in HLA Typing and Matching over the First 20 Years of the National Marrow Donor Program RegistryTransplantation and Cellular Therapy, 2008
- Efforts of the United States’ National Marrow Donor Program and Registry to improve utilization and representation of minority donorsTransfusion Medicine, 2008
- Reduced-Intensity Conditioning followed by Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Myelodysplastic Syndrome and Myeloproliferative DisordersTransplantation and Cellular Therapy, 2008
- Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemiaBritish Journal of Haematology, 2007
- Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)Blood, 2006
- Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensityLeukemia, 2005
- Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donorsBone Marrow Transplantation, 2004
- Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantationBone Marrow Transplantation, 2000